In vitro and in vivo study of aspirin loaded, electrospun polycaprolactone–maltodextrin membrane for enhanced skin tissue regeneration

Author(s):  
Mehdi Movahedi ◽  
Amin Orash Mahmoud Salehi ◽  
Davoud Moezi ◽  
Reyhaneh Yarahmadian
2008 ◽  
Vol 4 (4) ◽  
pp. 1057-1066 ◽  
Author(s):  
Sha Huang ◽  
Tianzheng Deng ◽  
Yijuan Wang ◽  
Zhihong Deng ◽  
Lisheng He ◽  
...  

2019 ◽  
Vol 137 ◽  
pp. 545-553 ◽  
Author(s):  
Sunaina Sapru ◽  
Subhayan Das ◽  
Mahitosh Mandal ◽  
Ananta K. Ghosh ◽  
Subhas C. Kundu

2018 ◽  
Vol 12 (5) ◽  
pp. 1195-1208 ◽  
Author(s):  
Povilas Daugela ◽  
Mindaugas Pranskunas ◽  
Gintaras Juodzbalys ◽  
Jolanta Liesiene ◽  
Odeta Baniukaitiene ◽  
...  

2013 ◽  
Vol 19 (3-4) ◽  
pp. 380-392 ◽  
Author(s):  
P.T. Sudheesh Kumar ◽  
N. Mincy Raj ◽  
G. Praveen ◽  
Krishna Prasad Chennazhi ◽  
Shantikumar V. Nair ◽  
...  

2020 ◽  
Vol 48 (3) ◽  
pp. 755-764
Author(s):  
Benjamin B. Rothrauff ◽  
Rocky S. Tuan

Bone possesses an intrinsic regenerative capacity, which can be compromised by aging, disease, trauma, and iatrogenesis (e.g. tumor resection, pharmacological). At present, autografts and allografts are the principal biological treatments available to replace large bone segments, but both entail several limitations that reduce wider use and consistent success. The use of decellularized extracellular matrices (ECM), often derived from xenogeneic sources, has been shown to favorably influence the immune response to injury and promote site-appropriate tissue regeneration. Decellularized bone ECM (dbECM), utilized in several forms — whole organ, particles, hydrogels — has shown promise in both in vitro and in vivo animal studies to promote osteogenic differentiation of stem/progenitor cells and enhance bone regeneration. However, dbECM has yet to be investigated in clinical studies, which are needed to determine the relative efficacy of this emerging biomaterial as compared with established treatments. This mini-review highlights the recent exploration of dbECM as a biomaterial for skeletal tissue engineering and considers modifications on its future use to more consistently promote bone regeneration.


2020 ◽  
Vol 21 (15) ◽  
pp. 1688-1698
Author(s):  
Germeen N.S. Girgis

Purpose: The work was performed to investigate the feasibility of preparing ocular inserts loaded with Poly-ε-Caprolactone (PCL) nanoparticles as a sustained ocular delivery system. Methods: First, Atorvastatin Calcium-Poly-ε-Caprolactone (ATC-PCL) nanoparticles were prepared and characterized. Then, the optimized nanoparticles were loaded within inserts formulated with Methylcellulose (MC) and Polyvinyl Alcohol (PVA) by a solvent casting technique and evaluated physically, for in-vitro drug release profile. Finally, an in-vivo study was performed on the selected formulation to prove non-irritability and sustained ocular anti-inflammatory efficacy compared with free drug-loaded ocuserts. Results: The results revealed (ATC-PCL) nanoparticles prepared with 0.5% pluronic F127 were optimized with 181.72±3.6 nm particle size, 0.12±0.02 (PDI) analysis, -27.4± 0.69 mV zeta potential and 62.41%±4.7% entrapment efficiency. Nanoparticles loaded ocuserts manifested compatibility between drug and formulation polymers. Moreover, formulations complied with average weight 0.055±0.002 to 0.143±0.023 mg, and accepted pH. ATC-PCL nanoparticles loaded inserts prepared by 5% MC showed more sustained, prolonged in-vitro release over 24h. In-vivo study emphasized non-irritability, ocular anti-inflammatory effectiveness represented by smaller lid closure scores, and statistically significant lowering in PMN count after 3h. Conclusion: These findings proposed a possibly simple, new and affordable price technique to prepare promising (ATC-PCL) nanoparticles loaded inserts to achieve sustained release with prolonged antiinflammatory efficacy.


Sign in / Sign up

Export Citation Format

Share Document